The therapeutic landscape in oncology is undergoing a profound shift with the rise of genome engineering technologies such as CRISPR/Cas9, base editing, and prime editing. These tools are enabling the precise correction of oncogenic mutations, the enhancement of immune cell therapies like CAR-T, and the development of synthetic lethality-based interventions.
A recent comprehensive review in Cell Reports Medicine outlines the growing potential of genome editing as a transformative cancer therapy. It also addresses the key challenges that remain, including safe and efficient delivery, minimization of off-target effects, and the ethical and regulatory complexities surrounding clinical implementation.
While most applications are still in early-phase development, the progress to date underscores the possibility of achieving durable, patient-specific, and potentially curative outcomes across both hematologic malignancies and solid tumors.
